Pub. Date : 2018 Oct 12
PMID : 30217442
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | Treatment of CML-derived K562 cells with BCR-ABL tyrosine kinase inhibitors, including imatinib, dasatinib, nilotinib and ponatinib, prevented activation of eIF2alpha kinases, protein kinase-like endoplasmic reticulum kinase (PERK) and general control nonderepressible 2, and downstream ATF4 induction during metabolic stress. | ponatinib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |